1.
Open Forum Infect Dis
; 8(2): ofaa653, 2021 Feb.
Artículo
en Inglés
| MEDLINE
| ID: mdl-33634203
RESUMEN
We assessed effectiveness and safety of concomitant chronic hepatitis C virus (HCV) treatment with direct-acting antivirals (DAAs) and multidrug-resistant tuberculosis (MDR-TB). Of 322 MDR-TB patients (19.4% HCV), 30 were treated concomitantly (23.3% human immunodeficiency virus-positive). Overall, 76.7% achieved HCV treatment success (95.8% among tested). One patient (3.3%) experienced a serious adverse event.